MICROSPHERE DRUG COATED MEDICAL DEVICES, MATERIALS AND METHODS

Information

  • Patent Application
  • 20230293780
  • Publication Number
    20230293780
  • Date Filed
    July 28, 2021
    3 years ago
  • Date Published
    September 21, 2023
    a year ago
Abstract
The field of materials and manufacturing methods involving single or multi-solvent, excipient and polymer-free drug coating formulations for production of microsphere coated drug delivery techniques.
Description
Claims
  • 1. A method of manufacturing a microsphere composition comprising at least one drug, comprising the steps of (1) dissolving the at least one drug in at least one solvent to form a hydrophobic mixture, (2) depositing the dissolved hydrophobic mixture onto a substrate and (3) evaporating the deposited, dissolved hydrophobic mixture from the substrate to yield the microsphere composition.
  • 2. The method of claim 1, wherein the at least one solvent is dry, and in particular contains less than 7% water.
  • 3. The method of claim 1, wherein the method further comprises a step (1a) of cleaning the substrate with an organic solvent.
  • 4. The method of claim 3, wherein the method further comprises a step (1b) prior to step (2) of applying a water-soluble material to the substrate and drying the water-soluble material.
  • 5. The method of claim 4, wherein the method further comprises a cleansing step by plasma treatment prior to step (1b) or (2).
  • 6. A medical device having a coating layer comprising a plurality of drug microspheres.
  • 7. The medical device of claim 6, wherein the medical device is a balloon catheter having a balloon.
  • 8. The medical device of claim 6, wherein the microspheres have an average diameter of 1 to 20 µm.
  • 9. The medical device of one of claim 6, wherein the coating layer consists of a plurality of drug microspheres.
  • 10. The medical device of claim 6, wherein the drug microsphere comprise or consist of at least one of rapamycin (sirolimus), everolimus, zotarolimus, biolimus, novolimus, myolimus, temsirolimus and/or rapamycin derivatives, including any pharmaceutically acceptable salts and hydrates, as well as any stereoisomers, mixtures of stereoisomers and racemates as well as a macrocyclic triene immunosuppressive compound, including any pharmaceutically acceptable salts and hydrates, as well as any stereoisomers, mixtures of stereoisomers and racemates, has the following structure: wherein R is C(O)—(CH2)n—X, n is 0, 1 or 2, X is a cyclic hydrocarbon having 3-8 carbons and optionally contains one or more unsaturated bonds.
  • 11. The medical device of claim 6, wherein the medical device comprises a primer layer comprising a water-soluble material.
  • 12. The medical device of claim 11, wherein the water-soluble material is a protein having a molecular weight of between 50 to 200 kD.
  • 13. The medical device of claim 7, wherein the balloon of the balloon catheter is made of a polyamide material.
  • 14. The medical device of claim 7, wherein the coating layer is applied to the surface of the balloon and consists of drug microspheres and wherein the coating layer is the only layer on the balloon.
  • 15. The medical device of claim 11, wherein the medical device is a balloon catheter having a balloon and wherein the primer layer is applied on the balloon and the coating layer consisting of drug microspheres is applied on the primer layer and wherein the balloon does not comprise any additional layer.
Priority Claims (1)
Number Date Country Kind
20202626.6 Oct 2020 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2021/071150 7/28/2021 WO
Provisional Applications (1)
Number Date Country
63058331 Jul 2020 US